Margaret E. Gatti‐Mays

Current Landscape of Immunotherapy in Breast Cancer

Sylvia Adams, Margaret E. Gatti‐Mays, Kevin Kalinsky et al. · JAMA Oncology · 2019 · 401 citations · Full text

Phase I trial of HuMax-IL8 (BMS-986253), an anti-IL-8 monoclonal antibody, in patients with metastatic or unresectable solid tumors

Marijo Bilušić, Christopher R. Heery, Julie Collins et al. · Journal for ImmunoTherapy of Cancer · 2019 · 256 citations · Full text

Association of Convalescent Plasma Therapy With Survival in Patients With Hematologic Cancers and COVID-19

Michael A. Thompson, Jeffrey P. Henderson, Pankil Shah et al. · JAMA Oncology · 2021 · 184 citations · Full text

Bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in patients with human papillomavirus-associated malignancies

Julius Strauss, Margaret E. Gatti‐Mays, Byoung Chul Cho et al. · Journal for ImmunoTherapy of Cancer · 2020 · 153 citations · Full text

A phase I study of the PD-L1 inhibitor, durvalumab, in combination with a PARP inhibitor, olaparib, and a VEGFR1–3 inhibitor, cediranib, in recurrent women’s cancers with biomarker analyses

Alexandra S. Zimmer, E. Hitt Nichols, Ashley Cimino‐Mathews et al. · Journal for ImmunoTherapy of Cancer · 2019 · 109 citations · Full text